Marc-Oliver Grimm

Marc-Oliver Grimm

[UroToday.com @urotoday]

3-weekly docetaxel 75 mg/m2 vs 2-weekly docetaxel 50 mg/m2 in combination with darolutamide + ADT in patients with #mHSPC – Results from the randomised phase 3 #ARASAFE trial. Presentation by @grimm_mo. #ESMO25 written coverage by @chavarriagaj > https://t.co/114a8eFLIq @myESMO @neerajaiims

[Daniel Heng @DrDanielHeng]

Join @AlbigesL @montypal @grimm_mo and I as we discuss #kidneycancer treatment updates and pearls at the Ipsen Symposium Saturday at 630pm @myESMO #ESMO25. Looking forward to great discussion! @OncoAlert @IKCCorg @CanUrolAssoc @kidneycan @KidneyCancer

[Medthority @Medthority]

Could a gentler chemo schedule be the "potential new standard" in mHSPC? Insights from @grimm_mo:

A 2-weekly approach with hormone therapy led to fewer severe side effects and lower rates of neutropenia and treatment-related death vs the standard 3-weekly dosing

#ESMO25 #MedX

[Tom Powles @tompowles1]

Biomarkers from adjuvant nivolumab(PD-1) vs placebo in UC shows ⬆️ TC PD-L1, CD4/8, IFNγ,TMB/APOBEC in responders & ⬆️TGFb in resistance @MattGalsky @NatureMedicine These result overlap with Avelumab in M1 disease (PD-L1) suggesting aligned but multifactorial response mechanisms.

[Carlos Alvarez @duemed]

@nataliagandur @Uromigos @tompowles1 @brian_rini These are the results… (be advise, low quality images).

@tompowles1 at #GUtrends25

[Dra. María Natalia Gandur Quiroga @nataliagandur]

💫🌟The @Uromigos are LIVE from #GUTrends25
@tompowles1 & @brian_rini break down the #UromigosScore 🧮 for Progression after 2L in #BladderCancer

How does it work?
🌐 18 experts
🔢 Score treatments from 0 to 3
📊 Mean score reflects expert consensus

Key insights:
➡️ Scenarios post-progression after prior therapies
⚖️ Treatment options in 3L+ setting
❗ Areas with consensus & where uncertainty still reigns

A practical, real-world snapshot for daily decisions!
#UroOnc #GU25 @OncoAlert

[Tom Powles @tompowles1]

The IMDC prognostic criteria is dynamic @TiansterZhang . A number of factors determine group allocation including, extent of tumour and progression. This accounts for patients moving across groups during progression. It’s not surprising it struggles to predict IO response #GU25

[high5md @high5md]

🚀 ASCO GU 2025: high5oncologyTV reporting live! 🎥🔬

📢 The latest breakthroughs in GU oncology – straight from ASCO GU 2025! Our high5oncologyTV experts are on-site, bringing you exclusive insights into the most important studies and results.

📅 From February 16, watch our full coverage – free & on demand at high5oncologyTV. 👉Create your free account now and stay up to date: https://t.co/hb8GWlJKPi

#ASCOGU25 #high5oncologyTV #GUOncology #ProstateCancer #BladderCancer #KidneyCancer #CancerResearch #MedicalUpdate

[Axel S. Merseburger @amerseburger]

Looking forward meeting @ProfHadaschik @ProfKHerrmann @grimm_mo @BellevilleErik at poster L27 "Prostate Cancer Real World Evidence Registry (PROCARE): Recurrent and metastatic prostate cancer" Study aims to enroll 5,000 patients in Germany #GU25 #ASCOGU25 #mHSPC #mCRPC @OncoAlert

[Tom Powles @tompowles1]

Big news👋. A positive R3 trial for PD-1 in NMIBC! The CREST trial evaluated sasanlimab (PD-1i)+BCG vs Standard BCG (induction and maintenance) in BCG-naïve, high-risk NMIBC.The study met its primary endpoint of EFS with ‘clinically meaningful’ results. https://t.co/8oRNdVgwZd

[Toni Choueiri, MD @DrChoueiri]

Huge congrats to @tompowles1 @Bartscancer who is changing GU Oncology landscape 1 trial at a time, all while doing other leadership things @myESMO @Annals_Oncology @Uromigos + much more …

[high5md @high5md]

📽️We are live! Watch our reports from #ESMO24, for free and on demand:
https://t.co/Q2VbIzqMBK
#high5oncologyTV

@StephenVLiu @DrRiyazShah @GriesingerFrank @MartinReck2 @NReguart @HendriksLizza @nicogirardcurie @DMSLung @HosseinBorghaei @RothschildSacha @OncoBellmunt @bjartell @scserendipity1 @nachoduranm @EfstathiouEleni @GoebellJ @grimm_mo @PGrivasMDPhD @HHammersMD @IvanyiPhilipp @y_loriot @amerseburger @weoncologists @declangmurphy @AndreaNecchi @tompowles1 @nealshore @montypal @E_de_Azambuja @evaciruelos @JavierCortesMD @CarmenCriscit @curijoey @RebeccaDSing @AgoStudy @ALEDIGNUS12 @Dlueftner @volkmar_mueller @BarbaraPistill2 @hoperugo @stolaney1 @myESMO

[onkowissen @onkowissen]

Spannende Daten zum #Prostatakarzinom vom #ESMO24. Diskutiert von den #onkowissenTV Fachleuten! Nicht verpassen!

@jcasusce @grimm_mo @ViktorGruenwald @GoebellJ @ProfHadaschik @ProfKHerrmann @IvanyiPhilipp @amerseburger @martin_schostak @Tilki_De

[Tom Powles @tompowles1]

Positive results from the NIAGARA Phase III trial showed durvalumab with neoadjuvant chemo then cystectomy had a statistically significant and clinically meaningful improvement in EFS & OS versus chemo/cystectomy alone in muscle invasive bladder cancer https://t.co/1kbyeoG50d…

[Toni Choueiri, MD @DrChoueiri]

@scserendipity1 @DrCols @AdamSharpMedOnc @MAWildgust @AlisonBirtle As an answer to that question, I quote the great Gary Lineker "Football is a simple game. Twenty-two men chase a ball for 90 minutes and at the end, the Germans always win", @Clara__Steiner @MichaelStaehler @ProfKHerrmann @grimm_mo

[UroToday.com @urotoday]

Post-progression survival of patients with #mHSPC who received darolutamide or PBO: Post hoc analysis of #ARASENS. Presented by @grimm_mo. #ASCO24 written coverage by @zklaassen_md @GACancerCenter > https://t.co/uT9wOWAGAT @ASCO

[Uniklinik Jena @uniklinik_jena]

Data from the phase 2 TITAN-TCC trial suggest that high-dose ipilimumab may be an appropriate salvage option for selected patients receiving nivolumab monotherapy as second-line treatment for metastatic urothelial carcinoma. @grimm_mo @CCCGLeipzigJena

[CancerNetwork® @CancerNetwrk]

Regarding the TITAN-TCC approach, 48% (Clopper-Pearson exact 90% CI, 0.34-0.61; 1-sided P <.001) of patients in first-line cohort 1 achieved a response, and 7% had a complete response. #blcsm | @grimm_mo

https://t.co/8sJ9yin8KW

[high5md @high5md]

#ESMO23 is off to a great start. Prof. @DLueftner and Prof. @amerseburger discuss their personal highlights so far and what they are looking forward to the next couple of days. Stay tuned! #esmo2023 #oncology #highlights #breastcancer #urology @myESMO

[Marc-Oliver Grimm @grimm_mo]

Now online at European Urology: Impact of prior cytoreductive nephrectomy in patients receiving Axitinib+Avelumab vs Sunitinib in JAVELIN RENAL 101
https://t.co/2I0Vfd1NEs